InvestorsHub Logo
Followers 85
Posts 1581
Boards Moderated 0
Alias Born 06/06/2012

Re: BioTechMaven post# 182550

Thursday, 05/18/2017 11:00:23 PM

Thursday, May 18, 2017 11:00:23 PM

Post# of 402872
Yep - CTIX doing their Ph2 PoC trials the right way... link below relevant to Kevetrin and Ovarian Cancer.

Prove your drug is more reality than mere concept, having done the early heavy lifting of sifting potential winners from definite losers (ID lead Compounds), test in humans and show compelling results, and Big Rx likely will step up and pay up.

Tick-tock. Tick-tock. Tick-tock.

B / P / K : Three strong shots on goal, Eden Hazard-like.

//

"Factors associated with failure of oncology drugs in late-stage clinical development: A systematic review"
(Jan 17)

Drug development in oncology is characterized by a high rate of failure at the stage of phase III trials.

Achieving proof of concept based on drug activity after a phase II trial increases the likelihood of later approval.

Drugs developed under a biomarker-based selection strategy are less likely to fail at late stages of development.

http://www.sciencedirect.com/science/article/pii/S0305737216301165

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent IPIX News